Biogen lays out three FDA decisions that could ramp up Alzheimer's drug launch
Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, Biogen CEO Chris Viehbacher said on Tuesday that there are a “number of ...
FiercePharma3d
Analysts tip Eisai, Biogen and Lilly to drive eightfold explosion in Alzheimer's market value
GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...
PMLiVE5d
Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug
Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...
Sarepta, Biogen drugs with accelerated approval under fire in FDA report
A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...
Benzinga.com6d
FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi ... Leqembi is indicated for Alzheimer’s disease ...
Alzheimer’s drugs eyed as next big obesity-like opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Sage confirms Biogen’s bid to acquire remaining stake
Sage Therapeutics (SAGE) stock jumped on Friday as Biogen (BIIB) made a bid to acquire the stake it currently doesn't own for ...
BioPharma Dive5d
At JPM, Biogen CEO tries to take down the deal temperature
While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...
BioPharma Dive7d
Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...
Bloomberg on MSN10d
Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Chattanooga Times Free Press7d
Alzheimer’s drugs eyed as next big obesity-like opportunity
Firms developing Alzheimer's drugs have already seen big peaks and troughs. Biogen shares soared 44% on a single day in November 2020 after news that an experimental drug appeared to be effective ...